Cargando…
Pediatric Melanoma and Drug Development
Importance—Pediatric melanoma occurs, albeit rarely. Should patients be treated by today’s medical standards, or be subjected to medically unnecessary clinical studies? Observations—We identified international, industry-sponsored pediatric melanoma studies triggered by regulatory demands in www.clin...
Autores principales: | Rose, Klaus, Grant-Kels, Jane M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5867502/ https://www.ncbi.nlm.nih.gov/pubmed/29558389 http://dx.doi.org/10.3390/children5030043 |
Ejemplares similares
-
Pediatric melanoma—The whole (conflicts of interest) story()
por: Rose, Klaus, et al.
Publicado: (2018) -
Questionable Industry-Sponsored Postneonatal Pediatric Studies in Slovenia
por: Rose, Klaus, et al.
Publicado: (2019) -
COVID-19 and Treatment and Immunization of Children—The Time to Redefine Pediatric Age Groups is Here
por: Rose, Klaus, et al.
Publicado: (2021) -
How Compounding Pharmacies Fill Critical Gaps in Pediatric Drug Development Processes: Suggested Regulatory Changes to Meet Future Challenges
por: MacArthur, Robert B., et al.
Publicado: (2022) -
Evolving treatments and future therapeutic targets in desmoplastic melanoma
por: Hadfield, Matthew J., et al.
Publicado: (2021)